欧洲和中国心脏调查预后和潜在的治疗意义-英文课件.ppt

Prescribed glucose lowering drugs 77 (17%) 1% 16% 1% 83% Insulin Oral drugs Combinations No prescription Newly detected diabetes n = 452 Not prescribed glucose lowering drugs 375 (83%) Glycemic control Experiences from the Euro Heart Survey Glucose lowering drugs at follow up in patients with newly detected diabetes (Anselmino et al; Europ Heart J 2008; 29:177) 1 1 0,90 0,92 0,94 0,96 0,98 1,00 Log rank test p=0.047 Yes No 0 100 200 300 400 Cumulative event free rate Time of follow up (days) Glucose lowering drug Euro Heart Survey diabetes and the heart Impact of glucose lowering drugs on 1-year CV-events (Kaplan-Meier) (Anselmino et al; Europ Heart J 2008; 29:177) 1 1 Euro Heart Survey diabetes and the heart HR for the impact of GLD on 1-year CV –events in newly detected DM 0.041 (0.05-0.97) 0.22 0.043 (0.02-0.97) 0.13 p (95%CI) HR 0.5 1.0 1.5 All-cause mortality/MI CV mortality, MI or stroke Variable Adjusted for age, sex, previous cardio-vascular diseases and use of evidence-based treatments (Anselmino et al; Europ Heart J 2008; 29:177) 1 1 Guideline recommendations Recommendation Class Level Improved control of post-prandial glycemia may IIb C lower CV risk and mortality Need for further research Available data promising 1 1 10th South China International Congress of Cardiology ACE trial symposium Prognostic and potential therapeutic implications of the European and China Heart surveys Time for questions 1 1 10th South China International Congress of Cardiology ACE trial symposium Prognostic and potential therapeutic implications of the European and China Heart surveys Lars Rydén Karolinska Institutet Stockholm, Sweden 1 1 Implications of the European and China Heart Surveys European Guidelines on Diabetes, prediabetes and Cardiovascular Disease may be downloaded from 1 1 Implications of the European and China Heart Surveys Diabetes and prediabetes is more com